Patient Focus: Sodium-Glucose Cotransporter-2 Inhibitor Rates for Patients with Heart Failure in the Veterans Affairs Health System. We Need to Move the Needle! An explanation of “Uptake of Sodium-Glucose Cotransporter-2 Inhibitors in Hospitalized Patients with Heart Failure: Insights from the Veterans Affairs Healthcare System”

In this issue of the Journal of Cardiac Failure, Dr. Anubodh Varshney and colleagues explore what influences the likelihood of prescription for Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) for United States ’ military veterans hospitalized with heart failure at Veteran's Affairs hospitals. SGLT2i are a relatively new class of medications that have been proven to reduce the chances of dying or being hospitalized due to heart failure.1,2 SGLT2i include medicines like dapagliflozin, empagliflozin, canag liflozin, and ertugliflozin.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research